Bullish
Pfizer's stock rises 1.7% to $29 after Q2 earnings beat and Depo-Provera settlement.
Pfizer's stock price increased by 1.7% to $29 following the release of its second-quarter 2026 earnings, which exceeded analyst expectations. Additionally, the company reached a confidential settlement covering over 6,000 federal Depo-Provera lawsuits, potentially reducing legal uncertainties.
Key points
- Pfizer reported adjusted earnings per share of $0.77 for Q2 2026, surpassing the consensus estimate of $0.68.
- The company achieved quarterly revenue of $15.03 billion, exceeding analyst expectations of $14.42 billion.
- Pfizer's stock reached a 52-week high of $29.09, marking a 20% increase year-to-date.
- Analysts maintain a consensus 'Hold' rating for Pfizer, with an average price target of $28.28.
Sources
AI-generated from public news sources. Not financial advice.
